Full text
Earnings transcript
Read the complete earnings call transcript.
CGC
Canopy Growth Corporation
$0.83
-0.02
(-2.33%)
| Exchange: | NASDAQ |
| Market Cap: | 349.164M |
| Shares Outstanding: | 320241 |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Luc Mongeau | |||||
| Full Time Employees: | 1128 | |||||
| Address: |
| |||||
| Website: | https://www.canopygrowth.com |
Canopy Growth Corporation (CGC), alongside its affiliated businesses, specializes in the cultivation, marketing, and retail of both cannabis and hemp-derived products. These offerings are designed for both recreational consumption and therapeutic uses, with its primary commercial reach extending across Canada, the United States, and Germany. The company structures its operations into two main divisions: Global Cannabis and a diverse portfolio of Other Consumer Products. Its extensive product range features dried cannabis flower, various extracts and concentrates, infused beverages, edible gummies, and vape cartridges. Canopy Growth distributes these items under numerous well-known brands, such as Tweed, 7ACRES, Martha Stewart CBD, and Spectrum Therapeutics, among others. Originally founded as Tweed Marijuana Inc., the enterprise adopted its current name, Canopy Growth Corporation, in September 2015. Established in 2009, the firm maintains its corporate headquarters in Smiths Falls, Canada.
Click to read more…
Revenue Segmentation
CGC full analysis
Hey everyone, welcome back to the channel where we break down stocks in a way that actually makes sense for real investors. Today we're diving deep into Canopy Growth, ticker CGC, a name that's been swinging around the cannabis space for years and still carries plenty of drama for anyone watching the charts. Let's kick things off with the bigger picture. Canopy Growth has been trying to stabilize after years of heavy losses and restructuring, and the market has been…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 297,146 | 268,995 | 284,603 |
| Gross Profit | 80,882 | 79,511 | 69,670 |
| EBITDA | -312,827 | -479,310 | -188,220 |
| Operating Income | -228,714 | -117,143 | -73,105 |
| Net Income | -657,269 | -598,115 | -262,908 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 912,427 | 1,118,732 | 1,118,732 |
| Total Liabilities | 428,014 | 421,138 | 421,138 |
| Total Stockholders Equity | 484,413 | 697,594 | 697,594 |
| Total Debt | 346,395 | 233,360 | 278,714 |
| Cash and Cash Equivalents | 113,157 | 364,683 | 364,683 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | -165,750 | -63,806 | -63,806 |
| Capital Expenditure | -10,813 | -5,333 | -5,953 |
| Free Cash Flow | -176,563 | -69,139 | -69,759 |
| Net Income | -600,666 | -262,908 | -262,908 |
| Net Change in Cash | -56,489 | 250,872 | 250,872 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 317,820.924 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 343,510.347 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 329,542.750 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 70,834.022 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 72,955.850 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 71,987.687 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | -22,091.188 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | -19,969.360 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | -20,937.523 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 199,931.758 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 216,092.215 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 207,305.613 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | -0.010 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | -0.010 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | -0.010 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 1 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Emphasis on operational improvements and cost efficiencies in Q3 fiscal 2025 earnings call supports potential for enhanced margins and streamlined operations.
- Strategic market expansions identified as core driver for future growth and profitability, leveraging existing revenue base.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about CGC valuation
Is Canopy Growth Corporation (CGC) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Canopy Growth Corporation (CGC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CGC a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CGC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CGC’s P/E ratio?
You can see CGC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CGC?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CGC a good long-term investment?
Whether CGC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CGC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-2.33
Trading Metrics:
| Open: | 0.86 | Previous Close: | 0.85 | |
| Day Low: | 0.82 | Day High: | 0.86 | |
| Year Low: | 0.81 | Year High: | 2.38 | |
| Price Avg 50: | 0.96 | Price Avg 200: | 1.04 | |
| Volume: | 2.365M | Average Volume: | 4.931M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
